Navigation Links
Kendle Leaders Adopt 10b5-1 Trading Plans
Date:3/7/2008

CINCINNATI, March 7 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Chairman and Chief Executive Officer Candace Kendle, PharmD, and President and Chief Operating Officer Chris Bergen have established prearranged trading plans to sell shares of the company's common stock over a designated period. The stock trading plans are part of their personal ongoing long-term strategy for tax planning and asset diversification and were adopted in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934 and Kendle's policy regarding stock transactions by its insiders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Under the trading plans, during a six-month period commencing March 20, 2008, and ending Sept. 30, 2008, Dr. Kendle and Mr. Bergen plan to sell up to 550,715 and 302,136 shares of KNDL common stock, respectively, in open market transactions. Transactions under this plan will be disclosed publicly by Dr. Kendle and Mr. Bergen through Securities and Exchange Commission filings.

Rule 10b5-1 permits insiders to implement a written plan to sell stock when they are not in possession of material non-public information and continue to sell shares on a regular basis even if they receive such information subsequently. Such plans establish predetermined trading parameters that do not permit the person adopting the plan to exercise any subsequent influence over how, when, or whether to affect trades. Using these plans, insiders can gradually diversify their investment portfolios, spread stock trades out over an extended period of time to reduce market impact, and avoid concerns about transactions occurring at a time when they might possess inside information.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip. Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
2. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
3. Kendle to Present at the Wachovia 2008 Healthcare Conference
4. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
5. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
6. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
7. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
8. Kendle to Present at the UBS Global Life Sciences Conference
9. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
10. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... Oregon and Pune, India , January 12, 2017 /PRNewswire/ ... vitro Toxicity Testing Market by Type and End Users - Global Opportunity Analysis and ... $7,813 million by 2022 from $2,921 million in 2015, growing at a CAGR of ... ... Allied Market Research Logo ...
(Date:1/11/2017)... California (PRWEB) , ... January 11, 2017 , ... ... to support fertility specialists with accurate and reliable preimplantation genetic screening (PGS). , ... have achieved excellent results,” says Ovation Fertility Genetics Scientific Director Amy Jones, ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... can make all the difference when navigating the challenges young businesses face. With ... into the extensive expertise and experience of Geoff DiMasi, Founder and Principal of ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):